For a long time, chemotherapy treatment has been the main method of cancer treatment. Chemotherapy treatment is the use of radiation to kill cancerous cells. The radiation often times affects both the cancerous cells and good cells. The effects of radiation are detrimental to the overall well-being of a patient. Seattle Genetics sought to find an innovative method in the treatment of cancer with Clay Siegall. The company sought to fill the gaps that are in the area of cancer research. It sought to find innovative techniques in the treatment of cancer.
Seattle Genetics developed Antibody-Drug Conjugates that seeks to specifically target cancer cells. The technology seeks to ensure that the good cells are not affected. This is a gentle approach in the treatment of cancer. It seeks to counter the negative effects of chemotherapy treatment. The ADCs are available in sixty five countries around the world and the use of this technology has revolutionized the treatment of cancer. The innovation of ADCs has given cancer patients a chance at life. The patients are now able to recuperate without dealing with the adverse effects that are associated with chemotherapy treatment. In addition to ADCs, Seattle Genetics is in the process of developing other line of drugs which are antibody therapies that would ensure that the treatment of cancer is effective and efficient.
Seattle Genetics has been in business since 1998. The company was first listed in the stock exchange in 2001. It has managed to raise six hundred and seventy five million dollars through public and private finance. The company also owns several licenses. It has collaborated with other industry players and this collaborations have enabled the companies to raise over three hundred million dollars. Seattle genetics is committed to the care of cancer patients. The company’s main mandate is to provide quality care for cancer patients and to meet their needs. The company also seeks to fill the gaps that are in oncology research.
Clay Siegall has been with Seattle Genetics from the onset. He is the co-founder of the company, the Chief Executive Officer and the chairman of the board. His leadership has propelled Seattle Genetics to its current position in the market.